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 Abstract 
Purpose:  To  evaluate  the  eﬃcacy  and  survival  rates  of  the  same  session  ab  interno  trabeculectomy  with 
trabectome  and  Baerveldt  glaucoma  implant  (BT)  compared  to  Baerveldt  implant  alone  (B). 
Method :  A  total  of  175  eyes  undergoing  primary  glaucoma  surgery  were  enrolled  in  this  retrospec ve 
compara ve  case  series,  including  60  eyes  which  underwent  BT  and  115  eyes  which  received  B  alone. 
Par cipants  were  iden ﬁed  using  the  procedural  terminology  codes,  and  their  medical  records  were 
reviewed.  The  primary  outcome  measure  was  surgical  success  deﬁned  as  5  mmHg  >  IOP  ≤  21  mmHg  and 
IOP  reduc on  ≥  20%  from  baseline,  no  reopera on  for  glaucoma,  and  no  loss  of  light  percep on  vision. 
Secondary  outcome  measures  were  intraocular  pressure,  the  number  of  glaucoma  medica ons,  and  best 
corrected  visual  acuity  (BCVA). 
Results :  The  cumula ve  probability  of  success  at  1  year  was  61%  in  BT,  and  50%  in  B.  IOP  decreased 
signiﬁcantly  from  23.6±8.9  mmHg  at  baseline  to  13.7±3.9  mmHg  at  the  ﬁnal  follow  up  in  BT  (P=  0.001). 
The  corresponding  numbers  for  B  were  23.3±7.5  and  14.2±4.5,  respec vely  (P=  0.001).  There  was  no 
signiﬁcant  diﬀerence  in  IOP  at  the  ﬁnal  follow-up  (P=0.56).  The  number  of  medica ons  at  baseline  was 
comparable  in  both  groups  (2.1±1.1  in  BT  versus  2.4±1  in  B,  p=0.07).  However,  BT  needed  sta s cally 
signiﬁcant  fewer  drops  in  all  postopera ve   me  intervals  and  used  0.9±0.9  (BT)  and  1.6±1.2  eyedrops  (B) 
at  the  ﬁnal  follow-up  visit  (P=  0.004).  No  dangerous  hypertony  or  hypertension  occurred  in  BT. 
Conclusion :  Similar  rates  of  success  and  IOP  reduc on  were  observed  in  BT  and  B.  Eyes  who  underwent 
trabectome  surgery  needed  signiﬁcantly  fewer  glaucoma  medica ons  during  1-year  follow-up  period 
while  tubes  did  not  require  fenestra on  resul ng  in  fewer  postopera ve  hypotony  or  hypertension. 
 
 
 
 
  
 Introduction 
The  main  surgical  interven ons  for  refractory  glaucoma  with  low  target  IOP  is  either  trabeculectomy  or 
glaucoma  drainage  devices  (GDD).  They  bypass  poorly  func oning  physiologic  ou low  and  drop  IOP 
below  episcleral  vein  pressure.  Trabeculectomy  is  associated  with  high  rate  of  annual  failure  and  a  wide 
range  of  sight-threatening  complica ons  [1–4] .  Moreover,  published  studies  indicate  that  glaucoma 
drainage  devices  have  the  same  or  higher  success  rate  than  trabeculectomy  in  the  management  of 
end-stage  glaucoma  with  signiﬁcantly  be er  safety  proﬁle  [1,  2,  5] .  As  such,  GDDs  are  becoming 
increasingly  used  for  wide  range  of  refractory  glaucomas  and  even  as  a  primary  procedure  for  advanced 
cases. 
One  of  the  most  frequently  implanted  GDDs  is  Baerveldt  implant  (Advanced  Medical  Op cs,  Santa  Ana, 
California,  USA).  In  contrast  to  valved  drainage  devices  such  as  Ahmed  valve  implant  (AGV)  (New  World 
Medical  Inc,  Rancho  Cucamonga,  California,  USA),  the  Baerveldt  implant  does  not  have  a  system  to 
control  the  intraocular  pressure  and  needs  intraopera ve  ﬂow  restric on  to  provide  enough   me  for 
ﬁbrosis  to  develop  around  the  plate  and  regulate  aqueous  ou low.  This  modiﬁca on  limits  immediate 
ﬂow  postopera vely  and  leads  to  uncontrolled  intraocular  pressure  [6] .  A er  approximately  1  month 
when  healing  takes  place  around  the  plate,  Baerveldt  results  in  excellent  IOP  control  [7] .  Since  GDDs  are 
mostly  implanted  in  severe  cases  of  glaucoma  with  advanced  op c  neuropathy,  this  postopera ve  ocular 
hypertension  may  have  a  detrimental  eﬀect  on  remaining  visual  func on.  Glaucoma  medica ons  are 
frequently  used  to  blunt  this  hypertensive  phase.  Repeated  exposure  to  high  concentra on  of 
preserva ves  especially  in  immediate  postopera ve  period  increase  the  chance  of  adverse  side  eﬀects 
and  hinders  compliance  [8,  9] . 
Alterna ves  are  making  fenestra ons  and  slits  anterior  to  the  liga on  or  passing  a  suture  into  the  lumen 
to  allow  for  limited  ﬂow  [10–12] .  Unfortunately,  these  approaches  have  a  variable  eﬀect  that  could  be 
anywhere  from  a  negligible  eﬀect  on  IOP  to  frank  hypotony  [11] .  As  a  minimally  invasive  glaucoma 
surgery  (MIGS),  ab  interno  trabeculectomy  (AIT)  with  trabectome  (NeoMedix,  Tus n,  CA,  USA)  remove 
trabecular  meshwork,  the  primary  site  of  ou low  resistance,  and  enhances  ou low.  The  procedure 
results  in  signiﬁcant  and  long-las ng  IOP  and  eyedrop  reduc on  with  excellent  safety  proﬁle  [13] . 
In  this  study,  we  present  our  experience  with  same  session  trabectome  surgery,  and  Baerveldt  compared 
to  Baerveldt  implanta on  alone.  We  hypothesized  that  combining  an  angle  procedure  to  enhance 
physiologic  ou low  with  shunt  procedure  provides  some  IOP  reduc on  un l  ligature  dissolves  and  the 
Baerveldt  implant  starts  to  func on. 
  
 
 
 
 Methods 
The  protocol  of  this  study  is  approved  by  ins tu onal  review  board  of  the  University  of  Pi sburgh 
Human  Subjects  Research  Commi ee.  Our  research  adhered  to  the  tenets  of  the  Declara on  of  Helsinki 
and  regula ons  of  the  Health  Insurance  Portability  and  Accountability  Act.  Pa ents  who  underwent 
either  Baerveldt  with  trabectome  surgery  (BT)  or  Baerveldt  implant  alone  (B)  between  2008  and  2015 
were  iden ﬁed  using  Current  Procedural  Terminology  codes.  All  procedures  were  performed  by  4 
glaucoma  fellowship-trained  surgeons.  Pa ents  older  than  18  years  old  with  medically  uncontrolled  IOP 
were  included  in  this  study.  Exclusion  criteria  were  neovascular  glaucoma,  uvei c  glaucoma,  and  history 
of  prior  ocular  surgery  (except  uncomplicated  phacoemulsiﬁca on). 
Data  were  collected  from  pa ents’  electronic  medical  record  and  included  basic  demographic 
informa on,  type  of  glaucoma  and  preopera ve  diagnosis,  preopera ve  IOP  and  number  of  glaucoma 
medica ons,  baseline  best  corrected  visual  acuity  (BCVA),  type  of  opera on,  postopera ve  IOP,  number 
of  medica ons,  and  BCVA. 
Primary  outcome  measure  was  success  deﬁned  as  IOP  ≤  21  mmHg  or  ≥  20%  reduc on  of  IOP  from 
baseline  at  two  consecu ve  visits,  no  need  for  further  glaucoma  surgery,  and  no  loss  of  light  percep on. 
The  secondary  outcome  measures  were  IOP,  BCVA,  and  the  number  of  medica ons. 
In  all  cases  the  IOP  was  measured  with  Goldmann  applana on  tonometer  (GAT;  Haag-Streit,  Konig, 
Switzerland)  at  1  day,  1  week,  4  ±1  week,  2-4  months,  5-7  months,  8-10  months,  and  11-13  months.  If 
more  than  one  visit  was  found  at  these  intervals,  the  visit  closest  to  month  6,  9,  or  12  was  chosen. 
Surgical  technique 
In  the  case  of  BT,  trabectome  (NeoMedix,  Tus n,  CA,  USA)  surgery  was  performed  ﬁrst.  Pa ent's’  head 
and  microscope  were   lted  30˚  away  from  the  surgeon.  A  temporal  1.6  mm  clear  corneal  incision  was 
created,  and  handpiece  was  advanced  into  the  anterior  chamber.  Tip  of  the  trabectome  was  engaged 
with  trabecular  meshwork  at  the  nasal  angle  and  advanced  parallel  to  Schlemm’s  canal  for  90˚ 
counter-clockwise  followed  by  a  90˚  clockwise  move  to  opposite  direc on  for  a  total  of  180˚  TM  abla on. 
The  handpiece  was  withdrawn  from  the  anterior  chamber  and  the  incision  was  hydrated  to  seal. 
Baerveldt  implanta on:  a  fornix-based  conjunc val  ﬂap  was  created,  and  tenon’s  dissec on  was 
advanced  toward  the  equator  un l  enough  space  was  created  for  the  implant.  The  lateral  wings  of  the 
350  mm*mm  Baerveldt  implant  were  advanced  under  the  superior  and  lateral  rectus  muscles.  The  plate 
was  sutured  to  the  sclera  10  mm  posterior  to  the  limbus.  The  tube  was  cut  short  with  the  bevel  up  to  an 
have  approximately  2-3  mm  intracameral  length.  The  tube  was  completely  ligated  near  the  plate  junc on 
with  a  7-0  polyglac n  910  suture  (coated  VICRYL,  Ethicon,  Somerville,  NJ,  United  States)  and  tested  with 
BSS  to  conﬁrm  water   ghtness.  The  tube  was  then  inserted  into  the  anterior  chamber  through  a  tunnel 
created  with  23-gauge  needle  and  secured  to  the  sclera  with  a  7-0  polyglac n  loop  s tch.  In  B,  but  not  in 
BT,  the  tube  por on  anterior  to  the  ligature  was  fenestrated  with  a  pass  of  the  spatulated  7-0  needle.  A 
 patch  gra   was  used  to  cover  the  tube.  The  conjunc va  and  Tenon’s  were  pulled  back  over  the  shunt  and 
sutured  to  the  limbus. 
At  the  conclusion  of  the  surgery,  an  an bio c  (moxiﬂoxacin)  and  steroid  (1%  prednisolone  acetate)  drop 
were  applied.  The  an bio c  was  used  four   mes  per  day  for  one  week  while  the  steroid  eye  drops  were 
used  4   mes  per  day  for  one  month  and  then  tapered  by  one  drop  applica on  per  week. 
Statistical  analysis 
All  analyses  were  performed  using  SPSS  so ware  (SPSS  Sta s cs  for  Windows,  Version  22,  Armonk,  NY, 
IBM  Corpora on)  To  describe  data,  frequency,  and  percent,  mean±SD,  median,  and  range  were  used.  To 
evaluate  the  baseline  diﬀerences  between  two  groups,  we  used  ANOVA,  Kruskal–Wallis,  Chi-Square,  and 
Fisher  exact  test. 
To  compare  the  rate  of  changes  between  two  groups  during  the  study  follow-ups  we  used  interac on 
analysis  within  a  linear  mixed  model.  To  compare  the  results  between  the  groups  adjusted  for  the 
baseline  values,  we  used  Analysis  of  Covariance  (ANCOVA) 
The  diﬀerence  in  IOP  and  number  of  glaucoma  medica ons  between  two  groups  were  assessed  by 
Mann-Whitney  test  and  independent  T-test. 
To  demonstrate  the  survival  of  subjects  in  the  groups,  Kaplan-Meier  survival  plots  were  constructed  and 
compared  using  the  log-rank  test.  Sta s cal  signiﬁcance  was  set  at  p<  0.05.  Success  was  deﬁned  as  the 
IOP  <21  mmHg  and  a  >20%  reduc on  from  baseline  with  no  need  to  further  surgery. 
Results  
A  total  of  175  eyes  were  included  in  this  study  consis ng  of  60  BT  and  115  B  alone.  Baseline  pa ent 
demographics  are  presented  in  Table  1.  The  mean  age  of  the  study  par cipants  was  71.7±11.1  years  in 
BT  and  66.2±15.7  years  in  B  (P=  0.016).  Eighty-eight  pa ents  (50.3%)  underwent  phacoemulsiﬁca on  at 
the   me  of  glaucoma  surgery,  36  eyes  (60.0%)  in  BT  and  52  eyes  (45.2%)  in  B  (P=0.063).  Primary 
open-angle  glaucoma  was  the  most  common  diagnosis  in  both  groups  (65.0%  and  56.5%  in  BT  and  B, 
respec vely,  P=0.516)  There  were  no  signiﬁcant  diﬀerences  between  the  study  groups  in  terms  of 
gender,  preopera ve  intraocular  pressure,  baseline  number  of  glaucoma  medica ons,  ethnicity,  and  type 
of  glaucoma  (Table  1). 
Kaplan-Meier  survival  curves  (Figure  1)  indicated  a  mean  dura on  of  survival  of  261.9±21.9  days  in  BT 
group  and  220.28±17.5  in  B  group  with  no  sta s cally  signiﬁcant  diﬀerence  between  two  groups  (log 
rank=2.53  p=  0.11).  The  cumula ve  probability  of  qualiﬁed  success  at  3  months,  6  months,  and  12 
months  was  74%,  64%,  and  61%  respec vely  in  the  BT,  and  66%,  52%,  and  50%  in  the  B.  In  subgroup 
analysis,  although  BT  combined  with  phacoemulsiﬁca on  had  longer  survival  than  B 
+phacoemulsiﬁca on,  the  diﬀerence  was  not  sta s cally  signiﬁcant.  The  mean  survival  dura on  was 
285.5±25.8  in  BT  with  phacoemulsiﬁca on  versus  225.8±25.9  in  B  with  phacoemulsiﬁca on,  log  Rank= 
2.17,  P=  0.14).  Corresponding  values  for  glaucoma  surgery  alone  were  221±37.2  and  215.5±23.6  in  BT 
 and  B  group,  respec vely  (log-Rank=  0.24,  p=  0.624,  Figure  1).  BT  combined  with  phacoemulsiﬁca on 
had  longer  survival  than  BT,  but  the  diﬀerence  was  not  sta s cally  signiﬁcant  (285.5±25.8  versus 
221±37.2,  Log-Rank=  1.18  P=  0.18).  Corresponding  values  for  B  were  225.8±25.9  and  215.5±23.6  in  B 
with  phacoemulsiﬁca on  and  B  alone,  respec vely  (log-Rank  =  0.45,  P=  0.50).  
IOP  was  decreased  signiﬁcantly  from  23.6±8.9  mmHg  at  baseline  to  13.7±3.9  mmHg  at  ﬁnal  follow  up  in 
BT  (P=  0.001,  Figure  2).  The  corresponding  numbers  for  B  were  23.3±7.5  and  14.2±4.5,  respec vely  (P= 
0.001).  IOP  varied  more  in  B  than  in  BT  during  the  early  postopera ve  phase  with  5.3%  of  hypotony  in  BT 
versus  13.6%  hypotony  in  B.  Overall,  during  the  1-year  follow-up,  9  (15%)  pa ents  in  BT  and  30  (26.3%) 
pa ents  in  B  group  experienced  hypotony,  respec vely,  but  due  to  the  rela vely  low  number  and  range 
of  pressures,  the  diﬀerence  was  not  sta s cally  signiﬁcant  (P=0.08).  Most  of  the  hypotony  episodes  were 
within  the  ﬁrst  month  before  suture  opening. 
There  was  no  signiﬁcant  diﬀerence  in  IOP  at  ﬁnal  follow-up  (P=0.56).  Eyes  in  BT  experienced  a  9±9.1 
mmHg  reduc on  in  IOP  within  1  week  a er  the  surgery  compared  to  a  6±12.3  mmHg  reduc on  in  B  (P= 
0.09,  Figure  2).  While  IOP  was  comparable  on  day  one  between  BT  with  phacoemulsiﬁca on  and  BT 
(20.3±11.1  mmHg  versus  18.6±12.7  mmHg,  P=  0.56).  B  with  phacoemulsiﬁca on  had  a  signiﬁcantly 
higher  IOP  on  day  1  compared  to  B  (25.2±16.4  versus  17.9±12.4,  P=0.008). 
The  baseline  number  of  glaucoma  medica ons  was  2.1±1.1  in  BT  and  2.4±1  in  B  (P=0.07,  Figure  3). 
However,  BT  needed  sta s cally  signiﬁcant  fewer  drops  in  all  postopera ve  visits.  At  the  ﬁnal  follow-up 
visit,  the  number  of  glaucoma  medica ons  was  0.6±0.9  drops  in  BT  and  1.8±1.2  in  B  (p<0.005,  Figure  3). 
The  mean  BCVA  at  the  baseline  was  0.64±0.85  logMAR  in  BT  and  0.55±0.75logMAR  in  B  (P=0.663). 
Corresponding  numbers  for  ﬁnal  follow-up  visit  was  0.72±1.07  logMAR  and  0.63±0.97  logMAR, 
respec vely  (P=  0.668).  
 
  
 Discussion 
BT  and  B  were  both  eﬀec ve  in  reducing  IOP.  The  IOP  reduc on  of  40%  at  1-year  follow-up  was  similar  to 
previous  reports  [14–16] .  While  there  was  a  trend  toward  greater  IOP  reduc on  following  BT  compared 
to  B  but  the  diﬀerence  did  not  reach  sta s cal  signiﬁcance.  However,  BT  required  signiﬁcantly  fewer 
medica ons  postopera vely. 
Early  complica ons  of  glaucoma  drainage  devices  include  hyphema,  shallow  or  ﬂat  anterior  chamber, 
tube-corneal  touch,  corneal  edema,  and  suprachoroidal  eﬀusion  [6,  17] .  These  complica ons  are  caused 
by  postopera ve  hypotony,  which  is  more  common  in  non-valved  devices  when  the  ﬂow  is  not  restricted 
and  when  fenestra on  of  the  tube  yield  excessive  ﬂow  [18] .  Complete  liga on  of  the  tube  can  prevent 
postopera ve  hypotony  [19–23] ,  but  high  postopera ve  IOPs  can  be  dangerous  to  eyes  with  advanced 
glaucoma  damage.  Therefore,  tube  liga on  is  mostly  carried  out  in  conjunc on  with  intraopera ve 
longitudinal  oriented  2  mm  fenestra ons  proximal  to  the  liga on  [18] .  Despite  this,  a  postopera ve 
hypertensive  spike  may  develop  secondary  to  ﬁbrosis  growth  around  the  fenestra on,  malfunc on  of  the 
slit  valves,  or  insuﬃcient  fenestra ons  [10,  24] .  Considering  the  limita ons  of  fenestra on,  we  proposed 
to  perform  trabectome  surgery  in  the  same  session  to  prevent  postopera ve  IOP  spikes.  Trabectome 
enhances  ou low  by  plasma-mediated  abla on  of  the  trabecular  meshwork  and  has  a  long  track  record 
of  eﬃcacy  and  safety  in  several  types  of  glaucomas  [13,  25–28] . 
Although  trabectome  is  in  the  family  of  minimally  invasive  glaucoma  surgeries  and  primarily  proposed 
for  mild  open-angle  glaucoma  cases  [28] ,  recent  studies  suggest  that  it  is  also  eﬀec ve  in  more  severe 
glaucomas  [29] .  Although  the  success  rate  of  trabectome  a er  failed  trabeculectomy  and  tube  shunt 
procedure  support  its  role  in  the  management  of  severe  glaucoma  [30,  31] ,  many  eyes  at  that  stage 
cannot  aﬀord  a  surgical  failure.  The  eﬀect  of  trabectome  is  immediate  and  controls  IOP  un l  absorbable 
liga on  suture  dissolves,  and  B  begins  to  func on.  In  contrast  to  fenestra on,  the  IOP  lowering  eﬀect  of 
trabectome  also  persist  a er  the  ligature  suture  is  absorbed  and  has  the  addi ve  eﬀect  to  reduce  the 
need  for  glaucoma  medica ons.  This  is  no  small  feat  as  nearly  half  of  all  glaucoma  pa ents  experience 
local  and  systemic  side  eﬀects  of  glaucoma  medica ons  [32] .  Adverse  eﬀects  from  medica on  are  an 
important  reason  for  non-adherence  [33]  and  can  also  jeopardize  the  success  of  glaucoma  surgery  [34, 
35] .  Conversely,  reducing  eye  drops  can  considerably  improve  the  quality  of  life  [36] . 
Since  cataract  and  glaucoma  frequently  coexist,  many  individuals  in  both  groups  underwent  cataract 
surgery  at  the  same   me.  IOP  in  BT  with  phacoemulsiﬁca on  was  not  signiﬁcantly  diﬀerent  from  BT 
alone,  reﬂec ng  prior  results  that  suggested  an  addi onal  IOP  reduc on  of  only  0.7±0.3  mmHg  when 
combined  with  trabectome  surgery  [37,  38] .  Although  phacoemulsiﬁca on  has  been  advocated  as 
providing  a  trabeculoplasty-like,  addi onal  IOP  reduc on  IOP  [39] ,  glaucomatous  trabecular  meshwork  is 
o en  unpredictable  and  can  result  in  IOP  spikes  [40,  41] .  We  observed  this  on  day  1  in  pa ents  in  B  with 
phacoemulsiﬁca on.  The  results  of  our  study  and  previous  reports  on  this  subject  show  that  this 
poten ally  dangerous  could  be  prevented  by  the  same  session  trabectome  surgery  [37] .  Conversely,  no 
severe  hypotony  was  seen  in  BT  that  did  not  require  tube  fenestra on.  
 There  are  several  limita ons  to  this  study.  Pa ents  were  not  randomized  to  each  treatment  group. 
Because  of  the  rela vely  small  number  of  par cipants,  we  did  not  apply  our  past  matching  techniques  of 
coarsened  exact  [37,  42,  43]  or  propensity  score  matching  [14] .  Addi onally,  this  study  was  conducted  at 
a  single  ter ary  academic  center,  so  the  results  can  not  easily  be  generalized  to  other  prac ce  facili es. 
In  summary,  we  found  that  Baerveldt  implants  with  same  session  trabectome  surgery  signiﬁcantly 
decreased  the  number  of  glaucoma  medica ons  and  avoids  both  severe  hypertension  and  hypotension, 
thereby  nega ng  the  need  for  tube  fenestra on.  
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 Tables 
Table  1.  Baseline  clinical  characteristics  of  patients  in  BT  and  B  group 
  
Total 
Group 
P   BT B 
Age Mean±SD 68.1±14.5 71.7±11.1 66.2±15.7 0.016† 
 
Median  (range) 
70.5  (20.6  to 
94.4) 
73.7  (25.2  to 
94.4) 
67.8  (20.6  to 
89.1) 
 
BCVA Mean±SD 0.58±0.78 0.64±0.85 0.55±0.75 0.663‡ 
 Median  (range) 0.3  (0  to  4) 0.3  (0  to  3) 0.3  (0  to  4)  
IOP Mean±SD 23.3±8 23.6±8.9 23.2±7.5 0.731† 
 Median  (range) 22  (6  to  52) 21  (10  to  52) 22.5  (6  to  44)  
Medications Mean±SD 2.3±1 2.1±1.1 2.4±1 0.076‡ 
 Median  (range) 2  (0  to  4) 2  (0  to  4) 3  (0  to  4)  
Gender Female 98  (56.0%) 38  (63.3%) 60  (52.2%)  
 Male 77  (44.0%) 22  (36.7%) 55  (47.8%) 0.158* 
Phaco No 87  (49.7%) 24  (40.0%) 63  (54.8%) 0.063* 
 Yes 88  (50.3%) 36  (60.0%) 52  (45.2%)  
Ethnicity White 107  (61.1%) 37  (61.7%) 70  (60.9%) 0.99** 
 African  American 63  (36.0%) 21  (35.0%) 42  (36.5%)  
 Other 5  (2.9%) 2  (3.3%) 3  (2.6%)  
Glaucoma POAG 104  (59.4%) 39  (65.0%) 65  (56.5%)  
XFG 11  (6.3%) 3  (5.0%) 8  (7.0%)  
PACG 17  (9.7%) 7  (11.7%) 10  (8.7%) 0.516** 
PG 8  (4.6%) 3  (5.0%) 5  (4.3%)  
 Other 35  (20.0%) 8  (13.3%) 27  (23.5%)  
 
BCVA:  best  corrected  visual  acuity;  IOP:  intraocular  pressure;  POAG:  primary  open  angle  glaucoma;  XFG: 
exfolia on  glaucoma;  PACG:  primary  angle  closure  glaucoma;  PG:  pigmentary  glaucoma.  ch†  Based  on 
t-test.  ‡  Based  on  Mann-Whitney  test.  *  Based  on  Chi-Square  test.**  Based  on  Fisher  exact  test. 
 
  
Figures 
Figure  1 
 
Figure  1.  A)  Kaplan-Meier  survival  plots  for  BT  and  B  with  success  defined  as  a  final  IOP  of  ≤  21  mmHg 
and  a  20%  reduction  from  baseline.  Success  rates  of  (BT)  and  B  was  similar  in  both  groups.  B)  survival 
plots  of  BT  and  B  for  subgroup  analysis  separated  by  B)  glaucoma  surgery  alone  and  C)  same  session 
phacoemulsification  (lower  right). 
 
 
  
Figure  2 
 
Figure  2.  IOP  in  B  and  BT.  A)  IOP  in  BT  was  similar  to  B  and  trended  towards  a  lower  average  although 
tubes  in  BT  were  not  fenestrated  and  trended  towards  a  lower  average  IOP.  B)  B  and  BT  as  stand  alone 
procedures.  C)  B  +  phaco  had  a  higher  IOP  on  day  1  compared  to  subsequent  IOPs.  No  such  peak  was 
seen  in  BT.  Mean±95%  confidence  interval.  
 
 
 
  
  
 
Figure  3 
 
Figure  3.  Preoperative  and  postoperative  mean  eyedrops  for  BT  and  B.  Mean  pre-  and  postoperative 
glaucoma  medications  for  subgroup  analysis  separated  by  glaucoma  surgery  only  (B)  and  same  session 
phacoemulsification  (C).  Represented  as  mean±95%  confidence  Intervals.  
 
 
  
